Search results for Ranibizumab

Ranibizumab Biosimilar – Anti-VEGF mAb – Research Grade, ProteoGenix, PX-TA1008

Description of Ranibizumab Biosimilar - Anti-VEGF mAb - Research Grade General information about Ranibizumab Ranibizumab is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the “wet” type of age-related macular degeneration (AMD, also ARMD), diabetic retinopathy, and macular edema due to branch retinal vein occlusion or central retinal vein occlusion. This product is for research use only.

Ranibizumab, Kyinno, KB-1021

Ranibizumab, Affinityimmuno, ab-131-ranibizumab

Ranibizumab, Abbexa, abx831026

Ranibizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting VEGFA, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Ranibizumab is an antibody fragment without the Fc portion and affinity-matured to more strongly bind VEGF-A.

Ranibizumab Antibody, Abbexa, abx376594

Ranibizumab Antibody is a rabbit polyclonal antibody for the detection of Ranibizumab.

Ranibizumab ELISA Kit, Abbexa, abx395078

Ranibizumab ELISA Kit is a quantitative ELISA kit for detection of Ranibizumab.Ranibizumab is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. Ranibizumab was developed by Genentech and is marketed in the United States by Genentech and elsewhere by Novartis, under the brand name Lucentis. Ranibizumab is used to treat wet age-related macular degeneration (AMD; an ongoing disease of the eye that causes loss of the ability to see straight ahead and may make it more difficult to read, drive, or perform other daily activities). It is also used to treat macular edema after retinal vein occlusion (an eye disease caused by blockage of blood flow from the eye that leads to blurry vision and vision loss), diabetic macular edema (an eye disease caused by diabetes that can lead to vision loss), and diabetic retinopathy (damage to the eyes caused by diabetes). It inhibits angiogenesis by inhibiting Vascular endothelial growth factor A (VEGF-A), and its effectiveness is similar to that of bevacizumab. Its rates of side effects also appear similar. However, ranibizumab typically costs $2,000 a dose, while the equivalent dose of bevacizumab typically costs $50.

Anti-Ranibizumab Polyclonal Antibody, AntibodySystem, PAD12601

Ranibizumab Biosimilar - Research Grade, ichor.bio, ICH4031

Research Grade Ranibizumab (HB941016), abinScience, HB941016